ArticleInflammation and regeneration2025
Acomys cahirinus develop lung stroma distortion but not fibrosis after bleomycin-induced injury.
Article in Inflammation and regeneration, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundSpiny mice (Acomys sp.) have a unique ability of scarless regeneration. Therefore, the transfer of models used in convenient laboratory mice to study fibrosis could be a prospective approach, enabling the identification of novel antifibrotic therapies.
methodsIn this study, we first applied a model of bleomycin-induced pulmonary fibrosis in Acomys cahirinus (Acomys), using Mus musculus C57BL/6 (Mus) as a control. Changes in lung tissue density were assessed using magnetic resonance imaging (MRI). The severity of fibrosis in lung tissue, as well as the deposition of extracellular matrix components, was assessed by histochemical analysis and morphometry (hematoxylin and eosin, Van Gieson). Data on the content of the main profibrotic proteins of the extracellular matrix, including collagen types I and IV, fibronectin, and fibronectin with EDA domain, were additionally validated by dot blotting. Changes in the number and localization of the main cell types contributing to the development of fibrosis (myofibroblasts, activated stromal cells, epithelium, M2 macrophages, leukocytes) were assessed by immunohistochemical analysis and morphometry. Statistical analysis was performed using GraphPad Prism software. Kruskal-Wallis H-test with the Dunn test and Mann-Whitney test was used for comparison between groups. Differences were considered significant when *p < 0.05.
resultsOur data demonstrate that Acomys can survive high doses of bleomycin, which are sub-lethal and lethal for C57/Bl6 mice strain. In the head-to-head study, we performed an MRI to reveal changes in lung density as well as analyzed the morphology of Mus and Acomys lungs together with the identification of cell types required for fibrotic development. In contrast to Mus, Acomys demonstrated a decrease in respiratory regions upon bleomycin administration, but "classical" signs of fibrosis, such as fibrotic focuses or extracellular matrix accumulation, are detected only in small areas.
conclusionsThe model of bleomycin-induced pulmonary fibrosis in Acomys is valid for the further investigation of possible mechanisms of resistance to damage-induced profibrotic stimuli.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.